News Room
News Room
News Room
2506, 2018
Castle Creek Pharmaceuticals Announces First Patient with Epidermolysis Bullosa Enrolled in Pharmacokinetics Study of Diacerein 1% Ointment
New multi-center Phase 1 study expected to enroll up to 20 people living with rare genetic condition that leads to extremely fragile skin PARSIPPANY, [...]
1605, 2018
Castle Creek Pharmaceuticals Receives FDA Rare Pediatric Disease Designation for Diacerein 1% Ointment for Epidermolysis Bullosa
PARSIPPANY, N.J., May 16, 2018 – Castle Creek Pharmaceuticals (CCP), a global company dedicated to delivering transformative therapies to patients with orphan dermatologic and other [...]
401, 2018
Castle Creek Pharmaceuticals to Participate in 5th Annual Dermatology Summit
Biopharma company developing therapies for orphan dermatologic conditions to present during Entrepreneurial Company Showcase PARSIPPANY, NJ – January 3, 2018 – Castle Creek Pharmaceuticals (CCP), [...]
2710, 2017
Castle Creek Pharmaceuticals Receives Partners in Progress Award from debra of America
Company recognized for clinical research in epidermolysis bullosa simplex at the 19th Annual debra of America Benefit PARSIPPANY, NJ – October 27, 2017 [...]
